Devonian Health Group Shares Significant Findings on Thykamine as Innovative Anti-Inflammatory Solution

Devonian Health Group Unveils Promising Anti-Inflammatory Drug: Thykamine™

In a major announcement on December 4, 2025, Devonian Health Group Inc., a biopharmaceutical company specializing in treating fibroinflammatory diseases, unveiled the publication of a transformative study detailing the efficacy of its lead drug candidate, Thykamine™. This peer-reviewed article, entitled "Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs," has been published in the reputable journal, Biomedicines.

Significant Findings from the Study

The study, co-authored by esteemed researchers, including Dr. Charles Lynde from the University of Toronto and others from Laval University and McGill University, compared Thykamine™ against six commonly prescribed anti-inflammatory medications. These included well-known corticosteroids like hydrocortisone and prednisone, along with non-steroidal treatments such as crisaborole and pimecrolimus. Researchers applied an in vitro model to analyze how these drugs affected immune-activated cells during inflammation.

The results were promising: Thykamine™ demonstrated superior inhibition of key inflammatory markers, including MCP-1, MIP-1α, and MIP-1β, compared to the other medications, revealing both higher potency and lower required concentrations, all while maintaining a commendable safety profile devoid of cytotoxicity.

A New Paradigm in Managing Chronic Inflammation

Chronic inflammation is not merely an inconvenience; it plays a significant role in a variety of serious health conditions, ranging from skin disorders like eczema to more severe systemic autoimmune diseases. Prolonged inflammation can trigger fibrosis, a critical process in which normal tissue is replaced by fibrous connective tissue, potentially leading to irreversible organ damage.

Devonian's publication underscores the transformative potential of Thykamine™ in addressing this critical medical need. By modulating inflammation through multiple pathways, it stands as a strong alternative that could offer both therapeutic efficacy and enhanced tolerability. Dr. André P. Boulet, Chairman and CEO of Devonian, stated, "The results with Thykamine™ are very encouraging. For too long, patients have had to choose between effectiveness and tolerability. Thykamine™ offers a real possibility of bridging that gap."

What is Thykamine™?

Thykamine™, the pioneering product from Devonian's SUPREX™ platform, is uniquely designed for addressing conditions linked to inflammation and oxidative stress. It has shown potential in treating various disorders, including ulcerative colitis and atopic dermatitis. Evidence supporting its effectiveness comes from a range of in vitro and in vivo studies, alongside results from clinical trials, including a significant Phase IIa study involving patients suffering from mild-to-moderate distal ulcerative colitis.

Devonian Health Group: A Leader in Pharmaceutical Innovation

Founded in 2015 and headquartered in Québec, Canada, Devonian Health Group is dedicated to pioneering drugs for autoimmune inflammatory conditions. Its rigorous research foundation and commitment to innovative therapeutic approaches highlight its resolve to meet unmet medical needs in this pressing healthcare area. Devonian, publicly traded on both the TSX Venture Exchange and the OTCQB Venture Market, is also actively engaged in developing high-value cosmeceutical products, maximizing its proprietary approaches.

In conclusion, the groundbreaking study published in Biomedicines not only elevates Thykamine™ as a noteworthy candidate in the anti-inflammatory domain but also cements Devonian Health Group's reputation as a trailblazer in pharmaceutical research and development, paving the way for potential advancements in chronic inflammation treatment.